Fig. 4.

NDAT inhibits ST6Gal1 expression and PI3K activity in colorectal cancer cells. a HT-29 cells (left-hand panel) and HCT116 cells (right-hand panel) were treated with gefitinib in the presence or absence of NDAT for 24 h. Total RNA was harvested, and qPCR was conducted for ST6Gal1 gene expression. N = 3. b HCT116 cells were treated with gefitinib, NDAT, or the combination for 24 h. Cells were harvested, and immunoblotting analyses were conducted with antiphosphorylated PI3K or anti-ST6Gal1 antibody. GAPDH was used as internal loading control. N = 4. Data are expressed mean ± SD; compared to the untreated control, *p < 0.05, **p < 0.01, ***p < 0.001, compared with control; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001, compared with NDAT; ^$p < 0.05, ^$$p < 0.01, ^$$$p < 0.001, compared with Gefitinib